Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Shmuel Yaccoby

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address933 Cancer Institute
4104 Outpatient Circle
Mail Slot # 776
Little Rock AR 72205
Phone501-686-8250
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentPhysiology and Cell Biology, College of Medicine


    Collapse Research 
    Collapse research activities and funding
    W81XWH2110601     (YACCOBY, SHMUEL)Sep 30, 2021 - Sep 29, 2025
    US Department of Defense
    Role of novel myeloma subpopulations in the disease progression and drug resistance
    Role: Principal Investigator
    BI     (YACCOBY, SHMUEL)Nov 6, 2012
    BioInvent
    Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo
    Role: Principal Investigator
    BI-505 ICAM-1     (YACCOBY, SHMUEL)Nov 6, 2012
    BioInvent
    Effect of BI-505 ICAM-1 antibody on growth of myeloma cells in vitro and in vivo
    Role: Principal Investigator
    R01CA134522     (VAN RHEE, FRITS)Aug 22, 2008 - Jun 30, 2014
    NIH
    Potentiating Natural Killer Cell Anti-Myeloma Effects
    Role: Co-Investigator
    Collaborative Research Agreement     (YACCOBY, SHMUEL)Dec 14, 2007 - Dec 13, 2009
    Celgene
    Anti-myeloma efficacy of PDACs/HPP
    Role: Principal Investigator
    CollaborativeResearchAgreement     (YACCOBY, SHMUEL)Dec 14, 2007 - Dec 13, 2009
    Celgene
    Anti-myeloma efficacy of PDACs/HPP
    Role: Principal Investigator
    CRA     (YACCOBY, SHMUEL)May 17, 2007 - Sep 17, 2008
    Vantia Therapeutics Ltd.
    Anti-myeloma efficacy of FAP inhibitor in ex vivo and in vivo systems for primary myeloma
    Role: Principal Investigator
    36     (YACCOBY, SHMUEL)Mar 1, 2007 - Aug 28, 2008
    Multiple Myeloma Research Foundation
    Targeting Dkk1 in multiple myeloma with humanized andti-DKk1 neutralizing antibody
    Role: Principal Investigator
    36-05     (YACCOBY, SHMUEL)Mar 1, 2007 - Aug 28, 2008
    Multiple Myeloma Research Foundation
    Targeting Dkk1 in multiple myeloma with humanized andti-DKk1 neutralizing antibody
    Role: Principal Investigator
    Velcade, No. 214619     (YACCOBY, SHMUEL)Dec 13, 2006 - Dec 13, 2007
    Millennium Pharmaceuticals, Inc.
    Study of Effect of VELCADE on Osteoblast Activity
    Role: Principal Investigator
    Velcade,No.214619     (YACCOBY, SHMUEL)Dec 13, 2006 - Dec 13, 2007
    Millennium Pharmaceuticals, Inc.
    Study of Effect of VELCADE on Osteoblast Activity
    Role: Principal Investigator
    29     (YACCOBY, SHMUEL)Oct 1, 2006 - Sep 30, 2008
    Multiple Myeloma Research Foundation
    Role of SPRPs in the anti-myeloma response of osteoblasts
    Role: Principal Investigator
    29-06     (YACCOBY, SHMUEL)Oct 1, 2006 - Sep 30, 2008
    Multiple Myeloma Research Foundation
    Role of SPRPs in the anti-myeloma response of osteoblasts
    Role: Principal Investigator
    ImmunoGen     (YACCOBY, SHMUEL)Oct 1, 2006 - May 2, 2008
    ImmunoGen, Inc.
    Effect of antiCD56-cytotoxic drug conjugate on myeloma cell growth in the bone marrow microenvironment ex vivo and in vivo
    Role: Principal Investigator
    PT     (YACCOBY, SHMUEL)Jul 31, 2006 - Nov 30, 2007
    Point Therapeutics, Inc
    Anti-myeloma efficacy of PT-100 and PT-630 in ex vivo and in vivo systems for primary myeloma
    Role: Principal Investigator
    PT-100/PT-630     (YACCOBY, SHMUEL)Jul 31, 2006 - Nov 30, 2007
    Point Therapeutics, Inc
    Anti-myeloma efficacy of PT-100 and PT-630 in ex vivo and in vivo systems for primary myeloma
    Role: Principal Investigator
    Research Agreement     (YACCOBY, SHMUEL)May 31, 2006 - May 31, 2009
    ZymoGenetics, Inc
    Effect of TACI-lg and BAFFR-lg on primary myeloma growth in SCID-hu mice
    Role: Principal Investigator
    28549 VELCADE CRA     (YACCOBY, SHMUEL)Dec 2, 2004 - Nov 30, 2006
    Millennium Pharmaceuticals, Inc.
    Effect of VELCADE on Myeloma Bone Disease and Tumor Progression in a SCID-rab model for Primary Lymphoma
    Role: Principal Investigator
    28549VELCADECRA     (YACCOBY, SHMUEL)Dec 2, 2004 - Nov 30, 2006
    Millennium Pharmaceuticals, Inc.
    Effect of VELCADE on Myeloma Bone Disease and Tumor Progression in a SCID-rab model for Primary Lymphoma
    Role: Principal Investigator
    SCID-hu mice ABT-510     (YACCOBY, SHMUEL)Oct 14, 2004 - Sep 30, 2007
    Abbott, Inc.
    Inhibition of primary myeloma by Thrombospondin-1 Peptide Mimetic in vivo
    Role: Principal Investigator
    R01CA093897     (YACCOBY, SHMUEL)Dec 1, 2001 - Nov 30, 2012
    NIH
    Myeloma-Microenvironment Interaction Dynamics
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Ling W, Johnson SK, Mehdi SJ, Alapat DV, Bauer M, Zangari M, Schinke C, Thanendrarajan S, van Rhee F, Yaccoby S. EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers (Basel). 2023 Sep 12; 15(18). PMID: 37760488.
      View in: PubMed
    2. Mehdi SJ, Ghatak K, Ling W, Johnson SK, Epstein J, Nookaew I, Zangari M, Schinke C, Thanendrarajan S, van Rhee F, Yaccoby S. Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leuk Res. 2023 10; 133:107355. PMID: 37499483.
      View in: PubMed
    3. Mikulasova A, Kent D, Trevisan-Herraz M, Karataraki N, Fung KTM, Ashby C, Cieslak A, Yaccoby S, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Morgan GJ, Asnafi V, Spicuglia S, Brackley CA, Corcoran AE, Hambleton S, Walker BA, Rico D, Russell LJ. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Res. 2022 07; 32(7):1343-1354. PMID: 34933939.
      View in: PubMed
    4. Schinke CD, Bird JT, Qu P, Yaccoby S, Lyzogubov VV, Shelton R, Ling W, Boyle EM, Deshpande S, Byrum SD, Washam C, Mackintosh S, Stephens O, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Barlogie B, van Rhee F, Walker BA. PHF19 inhibition as a therapeutic target in multiple myeloma. Curr Res Transl Med. 2021 07; 69(3):103290. PMID: 33894670.
      View in: PubMed
    5. Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, Ryan KR, Bauer MA, Wardell CP, Hoering A, Mavrommatis K, Trotter M, Deshpande S, Yaccoby S, Tian E, Keats J, Auclair D, Jackson GH, Davies FE, Thakurta A, Morgan GJ, Walker BA. Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma. Haematologica. 2020 04; 105(4):1055-1066. PMID: 31221783.
      View in: PubMed
    6. Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol. 2019 02; 184(4):578-593. PMID: 30408155.
      View in: PubMed
    7. Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 07 05; 132(1):59-66. PMID: 29784643.
      View in: PubMed
    8. Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clin Cancer Res. 2018 06 15; 24(12):2913-2919. PMID: 29563136.
      View in: PubMed
    9. Yaccoby S. Two States of Myeloma Stem Cells. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):38-43. PMID: 29066162.
      View in: PubMed
    10. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 09; 102(9):e364-e367. PMID: 28550191.
      View in: PubMed
    11. Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 08; 102(8):e313-e316. PMID: 28522572.
      View in: PubMed
    12. Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 07 06; 130(1):30-34. PMID: 28432222.
      View in: PubMed
    13. Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res. 2017 Jun; 32(6):1261-1266. PMID: 28240368.
      View in: PubMed
    14. Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res. 2017 Jun 01; 23(11):2665-2672. PMID: 27810902.
      View in: PubMed
    15. Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84. PMID: 26888183.
      View in: PubMed
    16. Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Mol Cancer Ther. 2016 Feb; 15(2):241-50. PMID: 26719576.
      View in: PubMed
    17. Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer. 2015 Nov 06; 15:864. PMID: 26545722.
      View in: PubMed
    18. Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica. 2015 Sep; 100(9):1214-21. PMID: 26022710.
      View in: PubMed
    19. Alagpulinsa DA, Yaccoby S, Ayyadevara S, Shmookler Reis RJ. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment. Cancer Biol Ther. 2015; 16(6):976-86. PMID: 25996477.
      View in: PubMed
    20. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285.
      View in: PubMed
    21. Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S. CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood. 2014 Sep 25; 124(13):2051-60. PMID: 25061178.
      View in: PubMed
    22. Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, Barlogie B, Epstein J, Qiang YW. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013; 8(9):e74191. PMID: 24066119.
      View in: PubMed
    23. Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun 06; 121(23):4753-7. PMID: 23603914.
      View in: PubMed
    24. Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol. 2013 Jun; 88(6):463-71. PMID: 23456977.
      View in: PubMed
    25. Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013 Jun; 41(6):547-557.e2. PMID: 23435312.
      View in: PubMed
    26. Li X, Ling W, Khan S, Yaccoby S. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res. 2012 Aug; 27(8):1635-48. PMID: 22460389.
      View in: PubMed
    27. Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B, van Hemert R, Angtuaco E, Brown T, Bartel T, McDonald J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica. 2013 Jan; 98(1):71-8. PMID: 22733020.
      View in: PubMed
    28. Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012 Sep; 97(9):1348-56. PMID: 22419581.
      View in: PubMed
    29. Li X, Ling W, Pennisi A, Wang Y, Khan S, Heidaran M, Pal A, Zhang X, He S, Zeitlin A, Abbot S, Faleck H, Hariri R, Shaughnessy JD, van Rhee F, Nair B, Barlogie B, Epstein J, Yaccoby S. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells. 2011 Feb; 29(2):263-73. PMID: 21732484.
      View in: PubMed
    30. Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, Shaughnessy JD, Yaccoby S. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One. 2010 Dec 20; 5(12):e15233. PMID: 21188144.
      View in: PubMed
    31. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011 Feb; 96(2):333-6. PMID: 20952514.
      View in: PubMed
    32. Jia D, Koonce NA, Halakatti R, Li X, Yaccoby S, Swain FL, Suva LJ, Hennings L, Berridge MS, Apana SM, Mayo K, Corry PM, Griffin RJ. Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiat Res. 2010 Jun; 173(6):809-17. PMID: 20518660.
      View in: PubMed
    33. Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol. 2010 May; 149(3):311-21. PMID: 20230410.
      View in: PubMed
    34. Yaccoby S. Advances in the understanding of myeloma bone disease and tumor growth. Br J Haematol. 2010.
    35. Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma. 2010 Feb; 51(2):213-20. PMID: 20038269.
      View in: PubMed
    36. Yaccoby S. Role of proteasome in bone formation and osteoclostogenesis. IBMS Bone Key. 2010; 4:147-55.
    37. Van Rhee F,, Szmania S,, Dillon, M,, Van Abbema A,, Li X,, Stone, M,, Garg TK,, Shi J,, Bost-Moreno AM,, Yun R,, Balasa B,, Ganguly B,, Chao D,, Rice AG,, Zhan F,, Shaughnessy J,, Barlogie B,, Yaccoby S,, Afar DEH. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc3) and bortezomib against multiple myeloma. Mol Cancer Ther. 2010; 2616-2624.
    38. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD, Zhan F. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010 Jan 07; 115(1):61-70. PMID: 19837979.
      View in: PubMed
    39. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep; 8(9):2616-24. PMID: 19723891.
      View in: PubMed
    40. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Barlogie B, Yaccoby S. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood. 2009 Aug 27; 114(9):1803-12. PMID: 19597185.
      View in: PubMed
    41. Li X, Ling W, Pennisi A, Khan S, Yaccoby S. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett. 2009 Nov 01; 284(2):175-81. PMID: 19446953.
      View in: PubMed
    42. Pennisi A, Li X, Ling W, Khan S, Gaddy D, Suva LJ, Barlogie B, Shaughnessy JD, Aziz N, Yaccoby S. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol. 2009 Jun; 145(6):775-87. PMID: 19388929.
      View in: PubMed
    43. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2009 Jan; 84(1):6-14. PMID: 18980173.
      View in: PubMed
    44. Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008 Oct 15; 112(8):3122-5. PMID: 18669874.
      View in: PubMed
    45. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood. 2008 Jul 01; 112(1):159-68. PMID: 18436739.
      View in: PubMed
    46. Qiang YW, Shaughnessy JD, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood. 2008 Jul 15; 112(2):374-82. PMID: 18344425.
      View in: PubMed
    47. Tian E, Landowski TH, Stephens OW, Yaccoby S, Barlogie B, Shaughnessy JD. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma. Mol Cancer Ther. 2008 Mar; 7(3):500-9. PMID: 18319333.
      View in: PubMed
    48. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia. 2008 Feb; 22(2):406-13. PMID: 18046446.
      View in: PubMed
    49. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol. 2007 Sep; 138(6):802-11. PMID: 17760811.
      View in: PubMed
    50. Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol. 2007 Sep; 82(9):831-3. PMID: 17546639.
      View in: PubMed
    51. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD, Barlogie B, Sanderson RD. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007 Sep 15; 110(6):2041-8. PMID: 17536013.
      View in: PubMed
    52. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007 Mar 20; 25(9):1121-8. PMID: 17296972.
      View in: PubMed
    53. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007 May 15; 109(10):4470-7. PMID: 17255354.
      View in: PubMed
    54. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007 Mar 01; 109(5):2106-11. PMID: 17068150.
      View in: PubMed
    55. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006 Oct; 10(4):295-307. PMID: 17045207.
      View in: PubMed
    56. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006 Sep; 7(2):109-14. PMID: 17026821.
      View in: PubMed
    57. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood. 2006 Sep 15; 108(6):2020-8. PMID: 16728703.
      View in: PubMed
    58. Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J, Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol. 2006 Apr; 133(1):83-92. PMID: 16512833.
      View in: PubMed
    59. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006 Feb; 91(2):192-9. PMID: 16461303.
      View in: PubMed
    60. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res. 2005 Nov 01; 11(21):7599-606. PMID: 16278377.
      View in: PubMed
    61. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005 Oct; 131(1):71-3. PMID: 16173965.
      View in: PubMed
    62. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med. 2005; 113:183-90. PMID: 15968103.
      View in: PubMed
    63. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood. 2005 Feb 01; 105(3):1303-9. PMID: 15471949.
      View in: PubMed
    64. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004 Mar 15; 64(6):2016-23. PMID: 15026338.
      View in: PubMed
    65. Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. Hematol J. 2003; 4(5):310-4. PMID: 14502254.
      View in: PubMed
    66. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 2002 Dec 01; 100(12):4162-8. PMID: 12393672.
      View in: PubMed
    67. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002 Jul 15; 100(2):610-7. PMID: 12091355.
      View in: PubMed
    68. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002 Feb; 116(2):278-90. PMID: 11841428.
      View in: PubMed
    69. Qiang YW, Kitagawa M, Higashi M, Ishii G, Morimoto C, Harigaya K. Activation of mitogen-activated protein kinase through alpha5/beta1 integrin is required for cell cycle progression of B progenitor cell line, Reh, on human marrow stromal cells. Exp Hematol. 2000; 28(10):1147 - 1157.
    70. Jaccoby S, Pinchasov Y, Snapir N, Robinzon B. Hypothalamic obese, functionally castrated hens are hypersensitive to estrogenic modulation of lipid metabolism. Physiol Behav. 1996; 60(3):913 - 918.
    71. Jaccoby S, Arnon E, Snapir N, Robinzon B. Effects of estradiol and tamoxifen on feeding, fattiness, and some endocrine criteria in hypothalamic obese hens. Pharmacol Biochem Behav. 1995; 50(1):55 - 63.
    72. Jaccoby S, Arnon E, Snapir N, Robinzon B. Effects of bilateral basomedial hypothalamic lesions on feeding, fattiness, and reproductive functions in the White Leghorn hen. Physiol Behav. 1994; 56(5):1081 - 1089.
    73. Jaccoby S, Snapir N, Rozenboim I, Arnon E, Meidan R, Robinzon B. Tamoxifen advances puberty in the White Leghorn hen. Br Poult Sci. 1992; 33(1):101 - 111.
    Yaccoby's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (332) concept(s)
    _
    Co-Authors Expand Description
    See all (29) people
    _
    Similar People Expand Description
    See all (35) people
    _
    Same Department Expand Description
    Search Department